Vaxart, Inc. (VXRT)
NASDAQ: VXRT · Real-Time Price · USD
0.6310
-0.0170 (-2.62%)
Mar 20, 2026, 4:00 PM EDT - Market closed

Revenue by Segment

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Discovery and Development of Oral Recombinant Protein Vaccines
237.26M28.70M7.38M107.00K892.00K
Discovery and Development of Oral Recombinant Protein Vaccines Growth
726.68%288.94%6796.26%-88.00%-77.95%
Total
237.26M28.70M7.38M107.00K892.00K
Total Growth
726.68%288.94%6796.26%-88.00%-77.95%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
United States
237.26M28.70M7.38M107.00K892.00K
United States Growth
726.68%288.94%6796.26%-88.00%-77.95%
Total
237.26M28.70M7.38M107.00K892.00K
Total Growth
726.68%288.94%6796.26%-88.00%-77.95%
Source: S&P Global Market Intelligence.